PDE-5 inhibitors tied to prostate cancer biochemical recurrence

PDE-5 inhibitors tied to prostate cancer biochemical recurrence

(HealthDay)—Phosphodiesterase type 5 inhibitor use after radical prostatectomy is associated with increased risk of biochemical recurrence, according to a study published in the February issue of The Journal of Urology.

Uwe Michl, from University Hospital Hamburg-Eppendorf in Germany, and colleagues examined the effect of phosphodiesterase type 5 on biochemical recurrence after for prostate cancer. Data were included for 4,752 consecutive patients with localized treated with bilateral nerve-sparing radical prostatectomy. Of these, 23.4 percent received phosphodiesterase type 5 inhibitors postoperatively. The risk of biochemical recurrence was compared for those who did and did not receive phosphodiesterase type 5 inhibitors. Patients were followed for a median of 60.3 months.

The researchers found that the five-year biochemical recurrence-free survival estimates were 84.7 percent in the phosphodiesterase type 5 inhibitor group and 89.2 percent in the nonphosphodiesterase type 5 inhibitor group. Phosphodiesterase type 5 inhibitor use was an for biochemical recurrence (hazard ratio, 1.38) in multivariate regression analysis, and the correlation persisted after propensity score matching.

"Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Urology

Copyright © 2015 HealthDay. All rights reserved.

Citation: PDE-5 inhibitors tied to prostate cancer biochemical recurrence (2015, January 29) retrieved 24 February 2024 from https://medicalxpress.com/news/2015-01-pde-inhibitors-tied-prostate-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Blood clue to prostate cancer recurrence


Feedback to editors